Effects of the DASH Diet Alone and in Combination With Exercise and Weight Loss on Blood Pressure and Cardiovascular Biomarkers in Men and Women With High Blood Pressure

The ENCORE Study

James A. Blumenthal, PhD; Michael A. Babyak, PhD; Alan Hinderliter, MD; Lana L. Watkins, PhD; Linda Craighead, PhD; Pao-Hwa Lin, PhD; Carla Caccia, RD; Julie Johnson, PA-C; Robert Waugh, MD; Andrew Sherwood, PhD

Background: Although the DASH (Dietary Approaches to Stop Hypertension) diet has been shown to lower blood pressure (BP) in short-term feeding studies, it has not been shown to lower BP among free-living individuals, nor has it been shown to alter cardiovascular biomarkers of risk.

Objective: To compare the DASH diet alone or combined with a weight management program with usual diet controls among participants with prehypertension or stage 1 hypertension (systolic BP, 130-159 mm Hg; or diastolic BP, 85-99 mm Hg).


Participants: Overweight or obese, unmedicated outpatients with high BP (N=144).

Interventions: Usual diet controls, DASH diet alone, and DASH diet plus weight management.

Outcome Measures: The main outcome measure is BP measured in the clinic and by ambulatory BP monitoring. Secondary outcomes included pulse wave velocity, flow-mediated dilation of the brachial artery, baroreflex sensitivity, and left ventricular mass.

Results: Clinic-measured BP was reduced by 16.1/9.9 mm Hg (DASH plus weight management); 11.2/7.5 mm (DASH alone); and 3.4/3.8 mm (usual diet controls) (P<.001). A similar pattern was observed for ambulatory BP (P<.05). Greater improvement was noted for DASH plus weight management compared with DASH alone for pulse wave velocity, baroreflex sensitivity, and left ventricular mass (all P<.05).

Conclusion: For overweight or obese persons with above-normal BP, the addition of exercise and weight loss to the DASH diet resulted in even larger BP reductions, greater improvements in vascular and autonomic function, and reduced left ventricular mass.

Clinical Trial Registration: clinicaltrials.gov Identifier: NCT00571844

Arch Intern Med. 2010;170(2):126-135

See also pages 121, 136, and 146
ments were repeated.

At the end of the 4-month treatment period, assess-
ment program (DASH-WM), or to the usual diet control (UC)
including a medical history and physical examination, measure-
was established during a series of screening visits that in-
cluded a medical history and physical examination, measure-
munication, environment, and time of day. After 5 minutes of quiet rest,
line change in arterial diameter relative to resting baseline from
Flow-mediated dilation was defined as the maximum percent-
ance between the proximal and distal arterial wall intima-
media interfaces using PC-based software (Brachial Analyzer,
version 4.0; Medical Imaging Applications LLC, Iowa City, Iowa).
Flow-mediated dilation was defined as the maximum percent-
age change in arterial diameter relative to resting baseline from
10 to 120 seconds after deflation of the occlusion cuff.

Flow-Mediated Dilation

Brachial artery flow-mediated dilation (FMD) was assessed fol-
lowing overnight fasting. Longitudinal B-mode ultrasono-
graphic images of the brachial artery, 4- to 6-cm proximal to the
anteceubital crease, were obtained using an Aspen ultra-
sound platform with an 11-MHz linear array transducer (Acu-
sion, Mountain View, California). Images were obtained after
10 minutes of supine relaxation and during reactive hyper-
emia, induced by inflating a forearm occlusion cuff to supra-
systolic pressure (approximately 200 mm Hg) for 5 minutes.
End-diastolic arterial diameters were measured as the dis-
tance between the proximal and distal arterial wall intima-
media interfaces using PC-based software (Brachial Analyzer,
version 4.0; Medical Imaging Applications LLC, Iowa City, Iowa).

Baroreflex Sensitivity

Beat-by-beat SBP and heart rate (HR) were collected using the
Finapres noninvasive BP monitor (model 2300; Ohmeda, Madison, Wisconsin). Recordings of beat-by-beat SBP and R-R
interval (derived as 60 000/HR) were edited for artifacts, lin-
early interpolated, and resampled at a frequency of 4 Hz to gen-
erate an equally spaced time series. A fast Fourier transform
was then applied to the interpolated data after detrending
and application of a Hanning filtering window. Baroreflex sensi-
tivity (BRS) was estimated from the magnitude of the transfer
function relating R-R interval oscillations to SBP oscillations
across the 0.07 to 0.1299 Hz, or low-frequency, band. Coher-
ence between SBP and R-R interval oscillations was required
to be at least 0.5 for measurements to be accepted as estimates
of BRS.

Left Ventricular Mass Index

Two-dimensional echocardiograms were acquired using an As-
pen imaging system and stored in a digital format for subse-
quent quantification by a single observer (A.H.) who was blinded
to treatment group. Left ventricular (LV) end-diastolic diam-
ereter, posterior wall thickness, and interventricular septal thick-
ness were measured at end-diastole, using a leading edge–to-
leading edge convention. Left ventricular mass was estimated
using a cube function model with a correction factor.11 To ad-
just for variations in heart size owing to differences in body size,
the LV mass index was calculated as LV mass divided by height11
as described by de Simone et al.12

Pulse Wave Velocity

Pulse wave velocity (PWV), measured using the Compilor de-
vice (Artech Medical, Pantin, France), was used as an index of
central artery stiffness.2 Pulse pressure waveforms were re-
corded from the right carotid and right femoral arteries, and
PWV (meters per second) was calculated from measurements
of pulse transit time (in seconds) and the distance (in meters)
traveled by the pulse between the 2 recording sites.

METHODS

PARTICIPANTS

The sample consisted of healthy, but overweight, men and women
with above-normal BP. Persons were eligible for study inclusion
if they were not taking antihypertensive medication and had a
mean systolic BP (SBP) of 130 to 159 or diastolic BP (DBP) of 85
to 99 mm Hg based on 4 screening visits. Other inclusion crite-
rion included age 35 years or older, body mass index of 25 to 40
(calculated as weight in kilograms divided by height in meters
squared), being sedentary, having no other medical comorbid-
ties that would preclude safe participation in the trial, and use of
any medications known to affect the cardiovascular system.

TRIAL OVERVIEW

The ENCORE (Exercise and Nutrition interventions for Car-
diOvasculaR HEalth) study was approved by the Institutional
Review Board at Duke University Medical Center. Written in-
formed consent was obtained from all participants.

Participants were recruited from physician referrals, community-
based screenings, and mass media advertisements. Eligibility
was established during a series of screening visits that in-
cluded a medical history and physical examination, measurement
of height and weight, and determination of baseline clinic-
measured BP. Following completion of baseline assessments,
participants were randomized to the DASH diet alone (DASH-A),
the DASH diet combined with a behavioral weight manage-
ment program (DASH-WM), or to the usual diet control (UC)
group. At the end of the 4-month treatment period, assess-
ments were repeated.

ASSESSMENTS

Clinic-Measured BP

Clinic-measured BP was determined according to JNC-7 guide-
lines. Potential participants were asked to refrain from smoking
or ingesting caffeine for at least 30 minutes before their appoint-
ment time. Measurements were standardized for cuff size, posi-
tion, environment, and time of day. After 5 minutes of quiet rest,
4 seated BP readings, each 2 minutes apart, were obtained using
a standard mercury sphygmomanometer and stethoscope. We
also obtained simultaneous automated BP recordings using an
Accutorr Plus BP monitor (Datascope, Mahwah, New Jersey)7
to provide an objective secondary approach to clinic BP mea-
surement. This clinic BP measurement protocol was repeated on
4 screening sessions over a 3 to 4 week period.

Ambulatory BP Monitoring

To assess BP during a typical day, participants wore an Accu-
tracker II (Suntech Medical Inc, Raleigh, North Carolina) am-
bulatory BP monitor.8 The Accutracker was programmed to rec-
ord BP measurements 4 times per hour throughout the waking
hours and 2 times per hour during sleep. The mean BP during
the entire 24-hour monitoring period, adjusted for posture, was
used for the primary analysis.

©2010 American Medical Association. All rights reserved.
Nutritional and Weight Assessment

An independent assessment of dietary and nutritional content was obtained by 2 separate self-report measures of diet: a retrospective food frequency questionnaire requiring participants to recall typical consumption during a 4-week period and a 4-day food diary. The food frequency questionnaire was analyzed by NutritionQuest (Berkeley, California), and the diary data were analyzed using Food Processor SQL Edition software, version 10.3 (ESHA Research, Salem, Oregon). In addition, sodium, calcium, and potassium intake were estimated from urinary excretion during a 24-hour period. Body weight was determined by a calibrated digital scale (Detecto; Cardinal Scale Manufacturing Co, Webb City, Missouri).

Cardiorespiratory Fitness

Participants underwent a maximal graded exercise treadmill test in which workloads were increased at a rate of 1 metabolic equivalent per minute. Expired air was collected by mouthpiece for quantification of minute ventilation, oxygen consumption, and carbon dioxide production with the Parvo Medics TrueOne measurement system (model 2400; Parvo Medics, Sandy, Utah).

RANDOMIZATION

On completion of the baseline assessments, participants were randomized in groups of 2 to 5 participants using a computer program. The size of the group was determined by how many eligible participants were available to be randomized within 4 weeks of their baseline BP assessments. Participants were provided their treatment group assignments in sealed envelopes; staff members performing the assessments were unaware of the group assignments. Assignments were stratified by clinic-measured BP, body mass index, and age.

INTERVENTIONS

Immediately following randomization, participants entered a 2-week controlled feeding period in which they ate according to the assigned dietary patterns (control diet, DASH diet, or a reduced-calorie DASH diet). For the UC and DASH-A arms, participants consumed study meals isocalorically so they would not gain or lose weight, whereas participants in the DASH-WM arm consumed meals at a 500-calories-per-day deficit to allow weight loss of about 1 pound a week. During the controlled feeding period, body weight was measured every other day to monitor participants’ weight stability or loss, allowing for adjustments in caloric intake. In addition, participants who were assigned to DASH-A or DASH-WM met with the nutritionist twice weekly for instruction about the DASH pattern. A 7-day menu cycle from the DASH-Sodium study for each dietary pattern at each of the 1600, 2100, 2600, 3100, and 3600 kcal energy levels was used as the basis for the recommended diets. We based caloric intake on the Harris Benedict formula, using screening weights and estimated physical activity levels derived from the Seven-Day Physical Activity Recall survey.

The control diet contained 34% of calories from fat (the average level for Americans based on the National Health and Nutrition Examination Survey Phase III data), whereas potassium, magnesium, calcium, and fiber levels were set at approximately the 25th percentile for average American intakes. Protein accounted for 13% of calories in the control diet and 18% in the DASH diet. The DASH diet is reduced in total fat (27%), saturated fat (6%), and cholesterol and contains about 3 times as much dietary fiber, potassium, magnesium, and calcium as the control diet. Because severe sodium restriction made a relatively small difference for those on the DASH diet, we used the current national recommended level (2400 mg/d per 2000 kcal). Following the initial 2 weeks of controlled feeding, participants were instructed to maintain the DASH diet on their own with (DASH-WM) or without (DASH-A) weight loss.

DASH Diet Alone

Participants in the DASH-A condition only received instruction in modifying the content of their diet to meet DASH guidelines. Participants in this group were explicitly asked not to exercise or to attempt to lose weight and to focus their attention only on what they ate. Participants received counseling on the DASH diet and were provided feedback on their adherence to the diet in weekly 30- to 45-minute small group sessions led by the study nutritionist. The goal of the weekly sessions was to assist participants in learning how to buy and prepare the appropriate foods, to enhance their motivation to choose to eat those foods, and to overcome obstacles to following the diet. Participants also were weighed each week to monitor their weight and to make adjustments in the recommended servings so that their weight would remain stable during the intervention period.

DASH Diet Plus Weight Management

Participants in the DASH-WM condition received the same instruction in the DASH diet as the DASH-A group, but their weekly 30- to 45-minute small group sessions also included a weekly cognitive-behavioral weight loss intervention and they attended supervised exercise sessions 3 times per week.

Cognitive-Behavioral Weight Loss. This intervention was based on cognitive-behavioral strategies and included Appetite Awareness Training, a self-monitoring strategy in which individuals learn to identify internal cues of moderate hunger and fullness and to use these cues to guide their eating behavior. The DASH recommendations were used to provide guidance regarding what to eat, whereas cognitive-behavioral strategies were designed to help individuals learn when/how to eat.

Supervised Exercise. Participants had supervised exercise sessions 3 times per week at a level of 70% to 85% of their initial heart rate reserve determined at the time of the baseline treadmill test. The supervised exercise routine consisted of 10 minutes of warm-up exercises, 30 minutes of biking and/or walking or jogging, and 5 minutes of cool-down exercises.

Usual Diet Controls

Participants in the UC condition were asked to maintain their usual dietary and exercise habits for 4 months until they were reevaluated. On a biweekly basis, their weight and BP were monitored and their health habits were assessed to ensure that they had not joined any exercise or weight-loss program and that maintained their body weight.

STATISTICAL ANALYSIS

The effect of treatment on the primary and secondary outcomes was evaluated using the general linear model function in SAS statistical software, version 9.1 (SAS Institute, Cary, North Carolina). Separate models were estimated for each outcome. The predictors in each model were 2 indicator variables carrying the orthogonal contrasts (DASH-WM and DASH-A vs UC and DASH-WM vs DASH-A) and the corresponding pretreatment value of the outcome, age, sex, and ethnicity (white vs nonwhite). We also adjusted for posture in the analysis of ambulatory BP and for arterial diameter at rest in the FMD analy-
sis. With respect to changes in aerobic capacity, exercise endurance, and weight-related variables, where DASH-WM was expected a priori to differ from the other 2 groups, we used 2 planned contrasts: DASH-WM vs DASH-A and DASH-WM vs UC. Data for all outcomes were analyzed following the intent-to-treat principle, with missing data managed using the multiple imputation method available in SAS PROC MI. We estimated that we would have about 80% power to detect a 0.5-SD difference between the active treatments and UC and a 0.6-SD difference between the 2 active treatments.

RESULTS

PARTICIPANT FLOW

Of the 3129 participants who initially inquired about the study, 449 (32.1) met our initial inclusion criteria. After screening, 144 participants (32.2%) were randomized: 49 to the DASH-WM condition (34.0%); 46 to DASH-A (31.9%); and 49 to UC (34.0%) (Figure 1).

PARTICIPANT CHARACTERISTICS

The mean age of the sample was 52 years; 38.9% of participants were African American, and 67.4% were women; the mean clinic-measured BP was 138/86 mm Hg. Most participants were college-educated and relatively affluent. The groups were generally comparable across the background variables (Table 1).

ATTENDANCE AT DIET AND EXERCISE SESSIONS

Attendance at the exercise and diet classes was excellent. Of the 42 expected exercise sessions, the median number attended was 38 sessions (90%). The median percentage time spent in the target HR range during exercise was 94%. The DASH class attendance also was excellent; for both intervention groups, the median number of sessions attended was 12 (92%).

CHANGES IN BODY WEIGHT

Adjusting for initial weight, age, sex, and ethnicity, the mean posttreatment weight for the DASH-WM group was significantly lower (84.5 kg) compared with the DASH-A (92.9 kg; P < .001) and UC (94.1 kg; P < .001) groups. The weight change was −8.7 kg in the DASH-WM group, −0.3 kg in the DASH-A group, and 0.9 kg in the UC group.

CHANGES IN DIETARY INTAKE AND URINARY EXCRETION

Participants in the 2 DASH treatment conditions showed excellent adherence to the DASH guidelines compared with those randomized to UC (Table 2). Participants in the DASH-WM condition also consumed significantly fewer total calories, less total protein, and fewer carbohydrates compared with those in DASH-A. Compared with UC, DASH-WM resulted in significantly lower urinary sodium levels and higher urinary potassium excretion (P < .01) (Table 3). The DASH-WM and DASH-A participants did not differ on any of the urinary excretion measures.

CHANGES IN AEROBIC FITNESS

The DASH-WM group exhibited greater improvements in peak VO₂ (oxygen consumption) and exercise endurance compared with the DASH-A and UC groups. Adjusting for pretreatment levels, age, sex, and ethnicity, the mean posttreatment peak VO₂ was higher among the DASH-WM participants (29 mL/kg/min) compared with those randomized to the DASH-A (23 mL/kg/min; P < .001) or UC (22 mL/kg/min; P < .001) condition. Participants in the DASH-WM group showed a 19% increase in peak VO₂ compared with negligible changes for participants in the DASH-A (−1.2%) and UC (−3.2%) conditions.
### Table 1. Background Characteristics of the Samplea

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Treatment Group</th>
<th>All Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DASH-WM (n=49)</td>
<td>DASH-A (n=46)</td>
</tr>
<tr>
<td>Age, mean (SD), y</td>
<td>52.3 (10)</td>
<td>51.8 (10)</td>
</tr>
<tr>
<td>Female sex</td>
<td>34 (69)</td>
<td>29 (63)</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>34 (69)</td>
<td>23 (50)</td>
</tr>
<tr>
<td>African American</td>
<td>15 (31)</td>
<td>22 (48)</td>
</tr>
<tr>
<td>Asian</td>
<td>0</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Level of education</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High school</td>
<td>15 (31)</td>
<td>14 (30)</td>
</tr>
<tr>
<td>Some college</td>
<td>4 (8)</td>
<td>4 (9)</td>
</tr>
<tr>
<td>Completed college</td>
<td>14 (29)</td>
<td>9 (20)</td>
</tr>
<tr>
<td>Postgraduate school</td>
<td>10 (20)</td>
<td>13 (28)</td>
</tr>
<tr>
<td>Other</td>
<td>6 (12)</td>
<td>6 (13)</td>
</tr>
<tr>
<td>Annual household income, $b</td>
<td>20 000 (5)</td>
<td>6 (13)</td>
</tr>
<tr>
<td>20-50 000</td>
<td>7 (14)</td>
<td>2 (4)</td>
</tr>
<tr>
<td>50-99 000</td>
<td>3 (6)</td>
<td>6 (13)</td>
</tr>
<tr>
<td>≥100 000</td>
<td>27 (55)</td>
<td>23 (50)</td>
</tr>
<tr>
<td>Weight, mean (SD), kg</td>
<td>93.9 (14)</td>
<td>93.0 (14)</td>
</tr>
<tr>
<td>Body mass index, mean (SD)c</td>
<td>33.5 (4.4)</td>
<td>32.8 (3.4)</td>
</tr>
<tr>
<td>Peak V˙O2 during treadmill test, mean (SD), mL/kg/min</td>
<td>23.4 (6.2)</td>
<td>23.8 (6.5)</td>
</tr>
<tr>
<td>Clinic-measured BP, mean (SD), mm Hg</td>
<td>138.7 (8.2)</td>
<td>137.6 (9.0)</td>
</tr>
<tr>
<td>Ambulatory BP, mean (SD), mm Hg</td>
<td>85.5 (6.8)</td>
<td>86.1 (6.1)</td>
</tr>
</tbody>
</table>

Abbreviations: BP, blood pressure; DASH-A, Dietary Approaches to Stop Hypertension alone; DASH-WM, Dietary Approaches to Stop Hypertension plus weight management; UC, usual diet controls; V˙O2, oxygen consumption.

aData are given as number (percentage) of participants unless otherwise indicated.

bOnly 123 reported their income. Of 144 participants, 7 in the DASH-WM, 9 in the DASH-A, and 5 in the UC group did not report an income.

cCalculated as weight in kilograms divided by height in meters squared.

### Table 2. Daily Dietary Intake After Treatment, Adjusted for Age, Sex, Ethnicity, and Pretreatment Level of Outcome

<table>
<thead>
<tr>
<th>Daily Dietary Intake</th>
<th>Treatment Group</th>
<th>Contrast P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DASH-WM (n=49)</td>
<td>DASH-A (n=46)</td>
</tr>
<tr>
<td>Servings per day, median (IQR)b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vegetable</td>
<td>5.5 (3.7-8.0)</td>
<td>5.6 (2.7-8.1)</td>
</tr>
<tr>
<td>Fruit</td>
<td>4.0 (3.0-4.3)</td>
<td>3.7 (2.1-3.8)</td>
</tr>
<tr>
<td>Dairy</td>
<td>1.8 (1.2-2.3)</td>
<td>1.9 (1.3-3.3)</td>
</tr>
<tr>
<td>Total calories, kcal</td>
<td>1648 (1521-1774)</td>
<td>1962 (1833-2090)</td>
</tr>
<tr>
<td>Protein calories, %</td>
<td>19.5 (18.7-20.4)</td>
<td>19.4 (18.6-20.3)</td>
</tr>
<tr>
<td>Carbohydrate calories, %</td>
<td>56.0 (54.4-58.2)</td>
<td>53.8 (51.9-55.7)</td>
</tr>
<tr>
<td>Fat calories, %</td>
<td>26.3 (24.7-27.9)</td>
<td>27.8 (26.1-29.4)</td>
</tr>
<tr>
<td>Saturated fat calories, %</td>
<td>7.6 (7.0-8.4)</td>
<td>8.0 (7.4-8.7)</td>
</tr>
<tr>
<td>Dietary cholesterol, mg</td>
<td>198 (162-234)</td>
<td>256 (220-293)</td>
</tr>
<tr>
<td>Fiber, g</td>
<td>25 (22-27)</td>
<td>26 (24-29)</td>
</tr>
<tr>
<td>Sodium, mg</td>
<td>1990 (1772-2208)</td>
<td>2044 (1825-2262)</td>
</tr>
<tr>
<td>Potassium, mg</td>
<td>3476 (3217-3735)</td>
<td>4047 (3785-4309)</td>
</tr>
<tr>
<td>Magnesium, mg</td>
<td>365 (333-394)</td>
<td>432 (393-454)</td>
</tr>
<tr>
<td>Calcium, mg</td>
<td>1023 (914-1132)</td>
<td>1175 (1065-1284)</td>
</tr>
</tbody>
</table>

Abbreviations: DASH-A, Dietary Approaches to Stop Hypertension alone; DASH-WM, Dietary Approaches to Stop Hypertension plus weight management; UC, usual diet controls.

bData are given as mean (95% confidence interval) unless otherwise indicated.

cP values are based on the Wilcoxon-Kruskal-Wallis rank sum test.
Compared with UC, the active treatments significantly lowered SBP ($P = .001$) and DBP ($P = .001$) (Figure 2). In addition, compared with DASH-A, the DASH-WM intervention resulted in significantly lower SBP ($P = .02$) and DBP ($P = .048$). Expressed as adjusted change from pretreatment to posttreatment, the reduction in SBP was 16.1 (95% confidence interval, 13.0-19.2) mm Hg in the DASH-WM group, 11.2 (8.1-14.3) mm Hg in the DASH-A group, and 3.4 (0.4-6.4) mm Hg in the UC group; the reduction in DBP was 9.9 (8.1-11.6) mm Hg in the DASH-WM group, 7.5 (5.8-9.3) mm Hg in the DASH-A group, and 3.8 (2.2-5.5) mm Hg in the UC group.

### Table 3. Urinary Excretion After Treatment, Adjusted for Age, Sex, Ethnicity, and Pretreatment Level of Outcome

<table>
<thead>
<tr>
<th>Daily Urinary Excretion</th>
<th>Treatment Group</th>
<th>Contrast P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium, mEq</td>
<td>DASH-WM</td>
<td>Active Treatments vs UC</td>
</tr>
<tr>
<td>114 (97-130)</td>
<td>125 (108-142)</td>
<td>.01</td>
</tr>
<tr>
<td>Potassium, mEq</td>
<td>DASH-A</td>
<td></td>
</tr>
<tr>
<td>71.1 (64-79)</td>
<td>74.9 (67-83)</td>
<td>.001</td>
</tr>
<tr>
<td>Phosphorus, mg</td>
<td>UC</td>
<td></td>
</tr>
<tr>
<td>783 (698-888)</td>
<td>860 (775-945)</td>
<td>.87</td>
</tr>
<tr>
<td>Calcium, mg</td>
<td>DASH-WM</td>
<td></td>
</tr>
<tr>
<td>138 (116-161)</td>
<td>167 (144-189)</td>
<td>.87</td>
</tr>
<tr>
<td>Creatinine, mg/dL</td>
<td>DASH-A</td>
<td></td>
</tr>
<tr>
<td>1.3 (1.2-1.4)</td>
<td>1.3 (1.2-1.4)</td>
<td>.60</td>
</tr>
<tr>
<td>Urea nitrogen, mg/dL</td>
<td>UC</td>
<td></td>
</tr>
<tr>
<td>9.2 (8.3-10.0)</td>
<td>10.2 (9.3-10.1)</td>
<td>.27</td>
</tr>
</tbody>
</table>

Abbreviations: DASH-A, Dietary Approaches to Stop Hypertension alone; DASH-WM, Dietary Approaches to Stop Hypertension plus weight management; UC, usual diet controls.

Data are given as mean (95% confidence interval).

---

**Figure 2.** Comparison of posttreatment means and 95% confidence intervals for clinic-measured blood pressure (BP) using an intent-to-treat model, adjusted for age, sex, ethnicity, and pretreatment BP. The contrasts between all active treatment groups and the usual diet control (UC) group were significant for both systolic (A) and diastolic (B) BP ($P < .001$), as were the contrasts between DASH-WM (Dietary Approaches to Stop Hypertension plus weight management) vs DASH-A (DASH alone) for systolic BP ($P = .02$) and diastolic BP ($P = .048$). The right panels display the pairwise differences (mean difference and 95% confidence interval) between the treatment groups calculated from the adjusted posttreatment means.

---

**PRIMARY END POINTS**

**Blood Pressure**

Compared with UC, the active treatments significantly lowered SBP ($P < .001$) and DBP ($P < .001$) (Figure 2). In addition, compared with DASH-A, the DASH-WM intervention resulted in significantly lower SBP ($P = .02$) and DBP ($P < .048$). Expressed as adjusted change from pretreatment to posttreatment, the reduction in SBP was 16.1 (95% confidence interval, 13.0-19.2) mm Hg in the DASH-WM group, 11.2 (8.1-14.3) mm Hg in the DASH-A group, and 3.4 (0.4-6.4) mm Hg in the UC group; the reduction in DBP was 9.9 (8.1-11.6) mm Hg in the DASH-WM group, 7.5 (5.8-9.3) mm Hg in the DASH-A group, and 3.8 (2.2-5.5) mm Hg in the UC group. The
The contrast between active treatments (DASH-A and DASH-WM) and UC also was significant for machine-read SBP (\( P / H_{11021} .001 \)) and DBP (\( P / H_{11021} .001 \)); in addition, the machine-read BP values were lower for the DASH-WM group compared with the DASH-A group for SBP (\( P = .01 \)) and DBP (\( P = .06 \)). Moreover, at the end of treatment, 19 (38.8%) UC group participants were classified as hypertensive (clinic BP \( \geq 140/90 \) mm Hg) compared with only 6 (12.2%) in the DASH-WM and 7 (15.2%) in the DASH-A groups.

Eighteen participants had missing or inadequate ambulatory BP readings either at baseline or posttreatment. These missing assessments were imputed using a multiple imputation model. Compared with the UC group, participants in the active treatment groups had significantly lower ambulatory SBP and DBP (\( P < .001 \)) (Figure 3). Ambulatory BPs were lower in the DASH-WM group compared with the DASH-A group for SBP (\( P = .01 \)) and DBP (\( P = .03 \)). Expressed as adjusted change from pretreatment to posttreatment, the reductions in ambulatory BP were: DASH-WM group, 10.2 (95% confidence interval, 6.8 to 13.6)/5.4 (3.4 to 7.4) mm Hg; DASH-A group, 5.3 (2.0 to 8.6)/2.9 (1.0 to 4.9) mm Hg; and UC group, 0.2 (3.4 to 7.4)/0.003 (–1.8 to 1.9) mm Hg.

**Cardiovascular Biomarkers**

The 2 DASH diet interventions resulted in lower PWV compared with the UC group (\( P = .001 \)), and PWV was lower in the DASH-WM group compared with the DASH-A group (\( P = .045 \)) (Figure 4). The 2 DASH treatment groups also tended to exhibit larger improvements in FMD than the UC group (\( P = .06 \)), but they did not differ from one another (\( P = .99 \)). For BRS, posttreatment results in the active treatment groups were not different than those in the UC group (\( P = .38 \)); however, greater improvements were seen in DASH-WM compared with DASH-A (\( P = .01 \)). The active treatment groups had lower posttreatment values for LV mass index compared with the UC group, but this difference was not significant (\( P = .26 \)); however, the DASH-WM intervention resulted in lower LV mass than did DASH-A (\( P = .02 \)).

**COMMENT**

Results of this randomized controlled trial demonstrate that the DASH diet produces significant reductions in BP compared with a typical American diet among unmedicated,
overweight or obese men and women with high BP and that weight loss and exercise combined with the DASH diet produce additional BP lowering. Compared with UC, we observed a 12.5/5.9 mm Hg net benefit in clinic-measured BP with the DASH-WM program consisting of aerobic exercise, caloric restriction, and cognitive-behavioral intervention and a 7.7/3.6 mm Hg net benefit with DASH-A. These findings confirm the value of the DASH diet in reducing BP and provide evidence for the significant “added value” associated with exercise and weight loss in the context of the DASH diet.

The efficacy of the DASH diet initially was established on the basis of several controlled feeding trials designed to examine the effects of dietary patterns on BP among unmedicated persons with higher-than-optimal DBP or with stage 1 hypertension; as a result of these studies, the DASH diet was adopted as part of current national recommendations for the prevention and treatment of high BP.1 The subsequent PREMIER study6 demonstrated the feasibility of implementing the DASH diet in daily life, but the small and non-significant BP differences between the DASH diet and the “established” intervention (which also involved some dietary changes) raised doubts about the added value of the DASH diet in optimizing BP. Because participants in the DASH plus “established” intervention lost more weight than the “established” intervention alone, the effects of the DASH diet could not be determined. The ENCORE trial has now extended the PREMIER study by not only examining the extent to which lifestyle modifications can be adopted in the home environment but also by manipulating the DASH diet intervention and weight loss independently. Our results confirm the findings of the earlier DASH feeding studies: participants who ate the DASH diet achieved significant BP reductions.3-5 However, adding exercise and weight loss led to an even greater decrease in BP.

The BP reductions achieved in our DASH-A and DASH-WM interventions were greater than those described in the PREMIER study and in other trials of lifestyle modification.22-24 The reasons for the greater benefit from the current ENCORE intervention could be attributed to the greater weight loss and excellent adherence to the DASH diet and exercise sessions. The 12/6 mm Hg relative reduction in BP that we observed among participants randomized to DASH-WM is equivalent to the BP lowering that physicians could expect from a high dose of an antihypertensive drug.25 Similar BP reductions have been achieved in placebo-controlled treatment trials and have resulted in a lowering of stroke risk by approxi-

Figure 4. Comparison of posttreatment mean (95% confidence interval) values for pulse wave velocity (A), flow-mediated dilation (B), baroreflex sensitivity (C), and left ventricular (LV) mass index (D) by treatment group, adjusted for age, sex, ethnicity, and pretreatment level of response variable. Flow-mediated dilation of the brachial artery also was adjusted for pretreatment arterial diameter at rest. Results of contrasts were as follows: for pulse wave velocity (A), all treatments vs usual diet controls (UC), P=.002, and DASH-WM (Dietary Approaches to Stop Hypertension plus weight management) vs DASH-A (DASH alone), P=.045; for flow-mediated dilation (B), all treatments vs UC, P=.06, and DASH-WM vs DASH-A, P=.99; for baroreflex sensitivity (C), all treatments vs UC, P=.38, and DASH-WM vs DASH-A, P=.01; and for left ventricular mass index (D), all treatments vs UC, P=.26, and DASH-WM vs DASH-A, P=.02.

©2010 American Medical Association. All rights reserved.
approximately 40% and a reduction in ischemic heart disease events by about 25%.26

In addition to BP lowering, we demonstrated improvements in important cardiovascular biomarkers. One of the structural consequences of high BP, left ventricular hypertrophy (LVH), is the strongest known predictor, other than advancing age, of cardiovascular morbidity and mortality. Increased LV mass predicts these clinical outcomes in hypertensive27 and healthy individuals,28 independent of other conventional risk factors. Drug therapy that results in LVH regression29 is associated with improved cardiovascular outcomes. For example, Verdecchia et al30 found a lower risk of cardiovascular events in hypertensive participants who had a decrease in LV mass during treatment, independent of baseline BP or the degree of BP reduction. Similarly, in a substudy of the Losartan Intervention of Endpoint Reduction in Hypertension (LIFE) trial, lowered LV mass was associated with decreased rates of cardiovascular events.31

Arterial stiffness also has been shown to be a strong independent predictor of cardiovascular morbidity and mortality.32-35 The DASH-A and the DASH-WM interventions resulted in greater reductions in PWV than UC, with more pronounced reductions among the DASH-WM participants. Dietary sodium intake was reduced by approximately 30% compared with UC, and participants in the DASH-WM group achieved a 19% improvement in aerobic capacity, which may have augmented the benefits of the DASH diet and weight loss on arterial stiffness. The observed reductions in PWV may be a result of the direct impact of diet and exercise as well as the lower BP resulting from these lifestyle changes. A reduction in arterial stiffness may also contribute to regression of LVH. The Ohasama study showed that arterial stiffness measured by PWV was related to LVH, independent of age and BP, in a population of 798 older adults.36 Ongoing trials should help clarify whether reducing arterial stiffness contributes to a lowered risk for cardiovascular events.37

Impairment of the sensitivity of the baroreflex system is an early consequence of hypertension38-41 and likely reflects reduced viscoelastic properties of the vascular wall housing the baroreflex stretch receptors owing to arterial stiffness and atherosclerosis.42-44 The DASH-A intervention did not alter BRS, but DASH-WM improved BRS by 33%. The improvements in BRS may result from reduced vascular stiffness45-47 or improved parasympathetic cardiac control through improved insulin sensitivity and glucose metabolism secondary to exercise and weight loss.48

The present study is limited by its relatively small sample of highly motivated participants along with a labor-intensive treatment program that may be difficult to fully implement in clinical practice. The ENCORE study was not powered to detect differences in “hard” clinical end points, such as stroke, myocardial infarction, and death. Trials of pharmacologic therapy, however, demonstrate that BP lowering reduces the risk of cardiovascular events and that the magnitude of BP reduction and reversal of cardiovascular structural changes associated with hypertension are key determinants of the effectiveness of therapy.49 Ultimately, the effects of the DASH diet and weight management will need to be evaluated prospectively in a larger sample of participants; longer-term follow-up of ENCORE study participants is currently ongoing. The present findings suggest that the DASH diet, particularly when augmented by exercise and weight loss, can offer considerable benefit to patients with high BP, not only through reductions in BP but through favorable modification of biomarkers of disease risk.

Accepted for Publication: September 9, 2009.

Correspondence: James A. Blumenthal, PhD, Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Campus Box 3119, Durham, NC 27710 (Blume003@mc.duke.edu).

Author Contributions: Drs Blumenthal, Bab yaw, Hinderliter, Craighead, and Lin had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Blumenthal, Bab yaw, Hinderliter, Craighead, Lin, and Sherwood. Acquisition of data: Blumenthal, Bab yaw, Hinderliter, Watkins, Lin, Caccia, Johnson, Waugh, and Sherwood. Analysis and interpretation of data: Blumenthal, Bab yaw, Hinderliter, Craighead, Lin, and Sherwood. Drafting of the manuscript: Blumenthal, Bab yaw, Hinderliter, Watkins, Lin, Johnson, Waugh, and Sherwood. Critical revision of the manuscript for important intellectual content: Blumenthal, Bab yaw, Hinderliter, Craighead, Lin, Caccia, and Sherwood. Statistical expertise: Bab yaw. Obtained funding: Blumenthal, Bab yaw, Hinderliter, Lin, and Sherwood. Administrative, technical, and material support: Blumenthal, Watkins, Caccia, Johnson, Waugh, and Sherwood. Study supervision: Blumenthal, Hinderliter, Craighead, Lin, and Sherwood.

Financial Disclosure: None reported.

Funding/Support: This study was supported by grant HL074103 from the National Heart, Lung, and Blood Institute; grant M01-RR-30 from the General Clinical Research Center; grant 5UL1RR024128-03 from the National Center for Research Resources; and the National Institutes of Health Roadmap for Medical Research.

Disclaimer: The contents of this study are solely the responsibility of the authors and do not necessarily represent the official view of the National Center for Research Resources or the National Institutes of Health.

Additional Contributions: The following ENCORE research staff members assisted with this trial: Lara LaCaille, PhD; Krista Barbour, PhD; Teresa Edenfield, PhD; Emily York-Crowe, PhD; Deborah Sebring, PhD; Marquisha Green, MA; Jennifer Jawanda, MA; Simon Bacon, PhD; Elizabeth Guillette, PhD; Steve Taxman, PA-C; Mark Feinglos, MD; Eugene Oddone, MD; Emily Ballard, BS; Beth Polisson, BA; Brian Beckman, BA; Katie Earnhardt, BA; Catherine Wu, BA; Kylie Stott, MA; Emily Hill, MA; Laura Jost, BA; Elizabeth Brenner, BS; Mark Taylor, MA; Jessica Tucker, MA; Sandra Kennedy, MA; Brad Gregory, MA; Jessica Hawkins, MA; Michael Ellis, BA; Susan Rohn, MA; and Elise Pangborn, MA. The data and safety monitoring board members are Mark Appelbaum, PhD; David Sheps, MD; and David Krantz, PhD. We thank the participants in this trial for their commitment to the trial and for their contribution to this research.

1. Joint National Committee on Prevention, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention,


